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a b s t r a c t
Background: Glioblastoma multiform (GBM) is the most common and most aggressive type of
primary brain tumour in humans. It has a very poor prognosis despite multi-modality treat-
ments consisting of open craniotomy with surgical resection, followed by chemotherapy
and/or radiotherapy. Recently, a new treatment has been proposed – Boron Neutron Cap-
ture Therapy (BNCT) – which exploits the interaction between Boron-10 atoms (introduced
by vector molecules) and low energy neutrons produced by giant accelerators or nuclear
reactors.
Methods: The objective of the present study is to compute the deposited dose using a natural
source of neutrons (atmospheric neutrons). For this purpose, Monte Carlo computer simu-
lations were carried out to estimate the dosimetric effects of a natural source of neutrons in
the matter, to establish if atmospheric neutrons interact with vector molecules containing
Boron-10.
Results: The doses produced (an average of 1Gy in a 1g tumour) are not sufﬁcient for
therapeutic treatment of in situ tumours. However, the non-localised yet speciﬁc dosi-
metric properties of 10B vector molecules could prove interesting for the treatment of
micro-metastases or as (neo)adjuvant treatment. On a cellular scale, the deposited dose
is approximately 0.5Gy/neutron impact.
Conclusion: It has been shown that BNCT may be used with a natural source of neutrons, and
may potentially be useful for the treatment of micro-metastases. The atmospheric neutron
ﬂux is much lower than that utilized during standard NBCT. However the purpose of the
proposed study is not to replace the ordinary NBCT but to test if naturally occurring atmo-
spheric neutrons, considered to be an ionizing pollution at the Earth’s surface, can be used
in the treatment of a disease such as cancer. To ﬁnalize this study, it is necessary to quantify
the biological effects of the physically deposited dose, taking into account the characteris-
tics of the incident particles (alpha particle and Lithium atom) and radio-induced effects
(by-stander and low dose effect). One of the aims of the presented paper is to propose to
experimental teams (which would be interested in studying the phenomena) a simple wayto calculate the dose deposition (allometric ﬁt of free path, transmission factor of brain).
© 2010 Greater Poland Cancer Centre, Poland. Published by Elsevier Urban & Partner Sp.
z.o.o. All rights reserved.
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Nomenclature
Dij dose deposited by the reaction i and thenucleus
j (Gy)
N0 total number of neutron (NU)
E energy variable (J)
t time variable (s)
S surface variable (m)
Nj number of nuclei j (NU)
V volume (m3)
ϕ cross section for reaction i and nucleus j (m2)
En
ij
energy deposited after the reaction i on the
nucleus j (J)
x depth (m)
m mass (kg)
 differential neutron ﬂux (J−1 s−1 m−2)
 density (g cm−3)
en/ attenuation coefﬁcient (J kg−1)
Ea,s,b neutron energy in air, skull and brain (J)
Ls,b,t mean free path (m)
Ts,b,t transmission factor for skull, brain and tumour
(NU)
Depth tumour depth in brain (m)
F(E) cumulative distribution function for neutron
related to energy (NU)
ni number of neutron with energy i (NU)
Na Avogadro constant (mol−1)
Aj atomicmassnumber for nucleus j (atomicmass
unit, u)
(E,j) total cross section for the nucleus j and the
energy E (m2)
PE,j capture probability onnucleus jwith the energy
E (NU)
mrec mass of recoil nucleus during elastic collision
(kg)
mn neutron mass=1.0087u
ϕrec deﬂexion angle in the system of the center of
mass (rad)
E0 energy of incident particle (J)
wr(E) weighting factor designed to reﬂect the differ-ent radiosensitivity of the tissues (NU)
Ei,f initial and ﬁnal neutron energy (J)
1. Background
In 2007, cancer caused about 13% of all human deaths (7.6 mil-
lion). Some of the most invasive malignant tumours are breast
cancer, colorectal cancer, lung cancer, and stomach and liver
cancer. Brain tumours are not very common as they account
for only 1.4% of all cancers in the United States. Patients with
benign gliomas may survive for many years, but in most cases
of glioblastoma multiforme (GBM), survival is limited to a few
months after diagnosis without treatment.1,2 Despite being
the most prevalent form of primary brain tumour, GBM occurs
in only 2–3 cases per 100,000 people in Europe and North
America. It is the most common and most aggressive type of
primary brain tumour in humans. The usual multimodalitydiotherapy 1 6 ( 2 0 1 1 ) 21–31
treatment consists of open craniotomy with surgical resection
of as much of the tumour as possible, followed by con-
current or sequential chemotherapy, antiangiogenic therapy
with bevacizumab, gamma knife radiosurgery, standard radio-
therapy, and symptomatic care with corticosteroids. Another
therapeutic approach is based on the Boron Neutron Capture
Therapy (BNCT) which was proposed in 1936 by Dr. Gordon
Lecher only 4 years after the discovery of the neutron.3–5 This
method, which is well adapted for intra-cranial cancer treat-
ments, is simple and well-designed in concept but complex
anddifﬁcult in execution. It is based on the capacity of thermal
neutrons to induce a reaction with Boron-10 nuclei, forming a
compound nucleus (excited Boron-11 in Eqs. (1) and (2)) which
then promptly disintegrates to Lithium-7 and an alpha par-
ticle (Fig. 1).6–8 Both the alpha particle and the Lithium ion
produce closely spaced ionizations in the immediate vicinity
of the reaction, with a range of approximately 4 and 8m,
for Lithium-7 and alpha particle respectively, or roughly the
diameter of one cell (10m).
10
5 B + 10n → 42He + 42Li + 2.79MeV (6%) (1)
10
5 B + 10n → 42He + 42Li + (0.48MeV) + 2.31MeV (94%) (2)
This technique is advantageous since the radiation damage
occurs over a short range and thus normal tissues can be
spared. The path of the reaction products is shown in Fig. 2.
The NBCT is a well recognized treatment for GBM, particu-
larly due to its efﬁciency, but is unfortunately very difﬁcult
to access as only a few radiotherapy units can use a pro-
ton accelerator.9,2 In France, this service is not available to
patients.
An alternative to this would be to ﬁnd a new source of
neutrons that is easily exploitable. Because free neutrons are
unstable (mean lifetime of about 15min), they can only be
obtained from nuclear disintegrations, nuclear reactions, or
high-energy reactions such as in cosmic radiation showers
or collision accelerators. Cosmic radiation interacting with
the Earth’s atmosphere continuously generates neutrons.10–15
The cosmic rays (essentially 85% of Hydrogen and 12.5% of
Helium) penetrate the magnetic ﬁelds of the solar system and
the Earth, and as they reach the Earth’s atmosphere, they col-
lide with atomic nuclei in the air (78% Nitrogen, 21% Oxygen
and 1% Argon) to create cascades of secondary radiation of
every kind. The intensity and energy distribution of differ-
ent particles that make up atmospheric cosmic radiation vary
in 3 essential parameters: altitude, location in the geomag-
netic ﬁeld (correlated to latitude, it deﬂects low-momentum
charged particles back into space), and time in the sun’s mag-
netic activity cycle.16–18 Table 1 shows the implication of the
ﬁrst two (altitude and latitude). Atmospheric shielding, cor-
related to altitude, is determined by the thickness of the air
mass above, called atmospheric depth.
At high altitude, geomagnetic latitude has a small effect
on the shape of the neutron spectrum and a very large effect
on the neutron radiative ﬂux. In Fig. 3, representing the results
found by Roesler in 1998,19 we can see how strong an inﬂuence
atmospheric depth has on the neutron ﬂux. It decreases by a
factor of 100 between high altitude (20km corresponding to an
atmospheric depth of 50 g cm−2) and sea level (corresponding
reports of practical oncology and radiotherapy 1 6 ( 2 0 1 1 ) 21–31 23
Fig. 1 – Schematic of 10B(n,)7Li capture reaction in a cancer cell (left), and total cross-section (right) versus energy ((n,0)
and (n,1)). Region 1 called low energy with mean cross section=2000b; Region 2 middle energy with mean cross
section=20b; Region 3 high energy with mean cross section=1b.
Fig. 2 – Penetration depth of alpha particle (1.47MeV) in the muscle at left. On the right, the zoom of the last micrometer.
Red points are the elastic scattering on hydrogenous nucleus, and green points the scattering of the secondary hydrogenous
particle (SRIM© calculator). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the
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o an atmospheric depth of 1000 g cm−2). Latitude is important
s there is an increase by a factor of about 10 between the
inimum intensity (at the Equator) and the maximum (at the
olar Regions).
The last parameter linked with the ﬂux of atmospheric
eutrons is solar variation. There are periodic components in
hese variations, mainly the 11-year solar cycle (or sunspot
ycle), but also the solar magnetic activity cycle. It modulates
he ﬂux of high-energy galactic cosmic rays entering the solar
ystem. As a consequence, the cosmic ray ﬂux in the inner
Table 1 – Relation between neutron ﬂux, altitude and geograph
Geographic location Atmospheric depth (g cm−2)
19◦N, 127◦W 53.5
54◦N, 117◦W 56
56◦N, 121◦W 101
38◦N, 122◦W 201
17◦N, 76◦W 1030solar system (or neutron ﬂux in the atmosphere) is correlated
with the overall level of solar activity.
2. AimThe atmospheric neutron ﬂux is much lower than that used
during standard NBCT (10n/s/cm2 vs. 109 n/s/cm2). Small as
this ﬂux may be, its characteristics are certainly compatible
for clinical use: free source for an ecological approach, frac-
ic location.
Altitude (km) Neutron ﬂuence rate (cm−2 s−1)
20.3 1.24
20.0 9.8
16.2 9.6
11.9 3.4
0 0.0127
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Fig. 3 – The depth dependence of the neutron ﬂux,
calculations for three different conditions. Polar region
(minimum and maximum) and equatorial region.
tionated dose to allow normal cells to recover, localised dose
deposition (only in tumour cells), and a disease being incur-
able (or hardly curable) with conventional tools. The purpose
of the proposed study is not to replace the ordinary NBCT, but
to test if naturally occurring atmospheric neutrons, consid-
ered to be an ionizing pollution at the Earth’s surface, can be
used in the treatment of adisease suchas cancer. Before begin-
ning the calculation, we know that atmospheric neutrons are
not candidates to be considered for a global and single therapy
(case of standard BNCT), however it is interesting to study the
ability of atmospheric neutrons to be used as an adjuvant or
neo-adjuvant treatment.
3. Materials and methods
3.1. BSH (Na2B12H12S1) and BPA(C9H12O4BN)
In clinical neutron capture therapy, 10B compounds such as
BPA and BSH have been widely used as short-range alpha
particle-producing agents.20–25 It is believed that BSH, which
has been clinically used in brain tumours, can pass through
the disrupted blood–brain barrier and thus selectively accu-
mulate in brain tumour tissue. BPA is an analogue of an
essential amino acid phenylalanine, and is actively taken up
in cells not only as an amino acid analogue for protein synthe-
sis, but also as a tyrosine analogue for melanogenesis. Owing
to this property, BPA has been clinically used for the treat-
ment of malignant cells. To characterise these molecules, it is
essential to quantify the nuclear reaction rate produced by the
interaction with atmospheric neutrons. In this ﬁrst study, we
are not considering the concentration and the biological dis-
tribution of these molecules in the organism. We hypothesise
that neutrons interactwith carriermolecules and simulate the
Table 2 – Nuclear reactions distribution after impact
between neutron and BPA or BSH.
Radiative capture (n,) (n,p) (n,n)
BSH 1% 94% ∼0% 5%
BPA 1% 88% ∼0% 11%diotherapy 1 6 ( 2 0 1 1 ) 21–31
different processes to establishwhich reactions aremost prob-
able. The estimation is done for all atmospheric neutrons (the
full spectra are used). The cross sections were produced using
ENDF/B library (available on http://t2.lanl.gov). Table 2 shows
that the two molecules used in the simulation are appropri-
ated for the neutron interaction: the alpha-producing reaction
reveals to be the most frequent one (94% for BSH and 88% for
BPA).
3.2. Analytic dose expression
Before analytically calculating the absorbed dose into
tissues1,26 resulting from a succession of interactions between
atmospheric neutrons and Boron nuclei, it is necessary to
assume that the dose is comparable to kerma (transferred
energy equals deposited energy) as the alpha and Lithium par-
ticles have a strong LET along with a very short pathway into
the matter. Eqs. (3) and (4) stand for the expression of the aver-
age on-laid dose after a succession of interactions between
neutrons and tissues. It becomes possible to deﬁne a mass
coefﬁcient of absorption denoted as (en/) in Eq. (5).
d3Dij =
d3N0
dEdt dS
Nj
V
ijE
n
ij
x
m
dEdt dS (3)
d3Dij = 
Nj
V2
ijE
n
ij
x

dE dt dS (4)
d3Dij = 
(
en

)
dEdt dS (5)
En
ij
is in fact equivalent to the Q-value of the reaction (default
or excess of mass during the nuclear reaction). In the case of
the radiative capture reaction, the value is nil as the dose will
not be laid-on into the volume V. This method of calculation
is relevant only in relatively simple cases. If we consider the
lowering of the incident ﬂux or a complex and heterogeneous
substance, thismethod is impractical. Therefore,wehave cho-
sen to use a hybrid or mixed method which combines both an
analytic model and Monte-Carlo type algorithms to quantify
the doses in use.
3.3. Modelling methodology
The characteristics of the matter (skull, brain and tumour)
are essential to simulate the absorbed dose. We have cho-
sen to use a detailed brain and skull composition as seen
in Table 3. The tumour is considered similar to the brain
(same chemical composition) with 20/g of Boron10 (aver-
age value found in the literature), representing 0.002% of a
tumour weighing 1g.3 The initial conditions are presented
in Fig. 4. To simplify the calculation, only some reactions
cross sections are chosen: (n,n), (n,) (n,p) and (n,).27 This
is a realistic hypothesis because other reactions are not fre-
quent with the speciﬁc energy of atmospheric neutrons, their
cross sections being too low. The simulation is done with the
Visual-Basic programming language and the ENDF/B library.
The computer used is a Xeon, 3GHz and 2GB (RAM). The
ENDF/B evaluations are the basis for the nuclear data library
used by radiation transport codes such as MCNP. The neutron
ﬂux spectrum used for the manipulation is measured at 12km
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Table 3 – Brain and skull characteristics.
Element Isotope Natural abundance (%) Skull mass fraction (%) s =1.5 g/cm Brain mass fraction (%) b =1.05 g/cm
H 1 99.985 3.4 9.5
2 0.015
C 12 100 15.52 18.5
O 16 99.862 43.54 65
17 0.138
N 14 99.634 4.2 3.5
15 0.366
Ca 40 96.941 22.51 1.5
42 0.647
43 0.135
44 2.086
46 0.004
48 0.187
P 31 100 10.31 1
S 32 95.02 0.3 0.2
33 0.75
34 4.21
36 0.02
Mg 24 78.93 0.21 0
25 10
26 11.07
K 39 93.26 0 0.4
40 0.01
41 6.73
Na 23 100 0 0.2
Cl 35 75.77 0
37 24.23
a
t
sFig. 4 – Numerical phantom simulation.ltitude and 45◦ latitude. The number of simulation events
ested oscillates between 6000 and 60,000, but experiments
how results are similar from 6000 simulations. The following0.2
sections describe different steps of the simulation, as listed in
Fig. 5.
3.3.1. Cumulative distribution function related to neutron
energy
The ﬁrst stage of the simulation determines the cumulative
distribution of neutron energy in the air. This means calcu-
lating the function F= F(E), described in Eq. (6), enabling to
allocate a random number between 0 and 1 to a neutron inci-
dent energy. There are 14.7neutrons/s/cm2 in this particular
case.
F(E) =
∑E
i=Eminni∑Emax
i=Eminni
(6)
Once the incident energy has been allocated, the simulation
requires estimating the interaction inside the brain and the
skull. The tools used are the mean free paths and the trans-
mission (attenuation) factors.
3.3.2. Attenuation factor and neutron capture
This parameter allows to quantify the number of neutrons
(only capture type) interacting in the brain and the skull. The
probability of neutron capture reactions is deﬁned in Eq. (7),
showing that the neutrons have merged to form a heavier
26 reports of practical oncology and radiotherapy 1 6 ( 2 0 1 1 ) 21–31
aticFig. 5 – Schem
nucleus.
PE,j = xNa
1
Aj
(E, j) (7)
The elastic and inelastic reactions (n,n) are not considered
in the expression of the total capture cross sections because
the neutrons continue to travel after impact. The transmission
factor is calculated from the precedent probability factor by
the expression T=1−∑ jPE,j. So, a coefﬁcient of zero means
the neutron is stopped in the matter and a coefﬁcient of 1
means there is no capture at all. In the intermediate case,
when the coefﬁcient ranges between 0 and 1, a random num-
ber between 0 and 1 is compared to the transmission factor T.
If this number is less than T, we consider there is no neutronmodel used.
capture, otherwise the neutron is captured and stopped in the
matter.
3.3.3. Mean free path
The mean free path of a particle is the average distance
covered by the neutron between successive impacts. Alter-
natively, it is the distance at which the intensity of particles
drops by 1/e. This coefﬁcient is calculated with the following
formula:
∑ AiL =
i
Na(E, i)
(8)
In the case of mean free path for capture, the (E, i) is
related to the reaction (n,) (n,p) and (n,), and for the
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Fig. 7 – Transmission factor for the skull (thickness 0.5 cm).
Table 4 – Mean free path in the brain, for the
atmospheric neutrons. The average is related to the
neutron energy distribution.
Energy L capture (cm) L elastic (cm)
0.025 eV< ···<0.5 eV 119 0.811
than 50MeV were not considered in this study because they
are only in small amounts and more complex reactions begin
to interfere. The allometric ﬁt for the mean free path between
two elastic collisions is given by Lb (cm)=0.81147+6.048.10−5Eig. 6 – Cumulative distribution function related to incident
nergy neutron.
lastic scattering (E, i), it is only related to the elastic
eaction.
.3.4. Elastic interaction
e consider the energy loss is possible only with the elastic
iffusion. All the capture reactions attenuate the beam but
o not modify the energy of the incident particle. In the case
f elastic collisions between neutrons and other particles, the
nergy lost is calculated in Eq. (9):
rec = E0 4mrecmn
(mrec + mn)2
cos2 ϕrec (9)
hen E0 < 10MeV, the reaction is isotropic and the cosine term
s replaced by the factor 1/2. If the collision is done with a
ydrogen nucleus, the expression of the energy loss by the
eutron is E0/2.
. Results
.1. Air stage
he cumulative distribution function related to the incident
eutron energy is represented in Fig. 6. This ﬁgure shows that
he energy of atmospheric neutrons is very low. A random
ssortment from this function reveals that 50% of neutrons
ave energy of less than 1MeV, and 80% of less than 10MeV.
.2. Skull stage
he thickness of the skull is about 0.5 cm, which generates a
eak attenuation, as shown in Fig. 7. The transmission factor
aries between 99.5% and 100%, meaning that very few neu-
rons are absorbed by the skull. The allometric ﬁt of the results
s described by Ts =0.99997−0.00162E (eV)−0.45609 (R2 = 0.995).
his manipulation is done by the Origin Pro software. The sec-
ndobservation is related to the elastic interaction in the skull.
he manipulation shows that the probability for a neutron to
ndergo an elastic interaction is less than 0.5%. In fact, the
eutron ﬂux is unchanged by crossing the skull.0.05 eV< ···<1keV 2360 0.815
1keV< ···<500keV 32,600 1.54
500keV< ···<50Mev 5460 8.58
0.025 eV< ···<50MeV 12,800 4.53
4.3. Brain stage
Without Boron (as in the healthy brain), neutrons have a
higher probability of undergoing an elastic scattering pro-
cess than a capture process. Table 4 shows the difference
between those two modes. Capture reactions are rare, while
those related to elastic collisions can be very frequent (every
1 cm for energies below 1KeV). Neutrons with energies higherFig. 8 – Transmission factor for the brain.
28 reports of practical oncology and raFig. 9 – Transmission factor for the tumour.
(eV)0.78671 (R2 = 0.999). The chosen method consists in deter-
mining whether, with this distance, the neutron will be
captured or will continue on its path. If it is not mitigated,
we consider it will lose some of its energy during the elas-
tic collision. This method is repeated until the neutrons cross
the brain and reaches the tumour. Fig. 8 shows the results
for the transmission of neutrons during the passage through
the brain. The analytic expression of this curve can be given
by a standard allometric equation: Ts =0.99943−0.003735E
(eV)−0.49955 (R2 = 0.999). We can observe that neutrons with
energy higher than 0.1 eV will not be altered, and will continue
on their path. During the simulations, we used the analytic
expression of the transmission coefﬁcients or the free average
distance, which greatly reduce computation time (42 s instead
of 15h for 6000 neutrons).
4.4. Tumour stage
As mentioned earlier, we consider that the tumour compo-
sition is equivalent to that of the brain comprising of Boron.
The mean free paths of elastic collisions are almost equiv-
alent to those shown in the previous section. However, the
transmission factor will be changed. Collisions like (n,) will
be predominant at low energy, amending the ﬁrst part of the
transmission curve of the tumour (Fig. 9). The procedure is the
same as that established in the case of the brain.
4.5. Model validation
To validate the model and the method of calculation, we
have made use of the SIEVERT calculation model (System of
information and evaluation of ﬂight exposure to cosmic radi-
ation in transports, as available on www.sievert-system.org),
a tool developed by IRSN. This tool allows quantifying the
dose received by aircrew during a ﬂight,28 which is associated
with the presence of neutrons at that altitude. Thus, we could
compare the results given by our methodology with those
established by the IRSN. In this manipulation, the numerical
phantom does not contain Boron or tumour. We only simu-
lated a ﬂight and calculated the dose deposited in a cylindricaldiotherapy 1 6 ( 2 0 1 1 ) 21–31
model representing a person. The SIEVERT cuts airspace in
265,000 stitches according to altitude, latitude and longitude
and then assigns them a dose rate (recalculated every month).
For a ﬂight from Paris to New York, the software simulates an
effective dose of 6.1Sv/h. We have made large approxima-
tions with the available data. The spectrum used corresponds
to the one applied during the previous manipulation, for a
similar latitude but at a different solar period. The simula-
tion target is a cylinder 20 cm×1.80m with a weight of 56.5 kg.
Its composition is the same as that previously described for
the brain. As before, there are very few capture reactions. Fur-
thermore, the only reactions of interest to us are the elastic
reactions (n,n), the deposit dose caused by the recoil nucleus.
The average energy transferred to the cylinder is calculated
by D¯ = m−1
∑
(Ef − Ei)wr(E). The result of 4.37Sv/h implies a
difference of 30% with the reference SIEVERT. However, the
numerous approximations make this result interesting and
in accordance with the requirement we have set ourselves,
namely to only work within the order of magnitude validat-
ing the interaction of atmospheric neutrons with the nuclei of
Boron-10.
4.6. Dosimetric aspect
The study of El Moussaoui et al.29 shows that pre-ﬁltering the
neutron beam allows to ameliorate the registered depth dose,
the incident energy of neutrons must be reduced to between
1eV and 10keV. To obtain this value, the Moroccan team sim-
ulated different “neutron decelerators” and noted the results.
Inspired by this study, we studied the effects of a decelera-
tor formed by water on the incidental spectra of neutrons. By
interposing 10 cm (or 20 cmwith less impact) ofwater between
the beam and the test patient, we considerably increased the
proportion of neutrons with energies ranging between 1eV
and 10keV. The chosen simulation conditions are the atten-
uator of 10 cm of water, a crane thickness of 0.5 cm and a
tumour of 1 cm containing 20g of Boron-10. The simulation
is made with 6000 incident neutrons. In addition to chang-
ing the spectrum, the attenuator induced a neutron loss of
5% (capture reaction), but these are neutrons that would not
have been able to reach the tumour because they mostly had
a very low energy (Fig. 10). 5.6% of incident neutrons inter-
act with the tumour, implying that the average dose to the
tumour is in the order of 1Gy for 1h of irradiation (3000 inter-
actions). We see that the value of the mean absorbed dose
within the tumour is very low, so the use of this technique as
a sole therapy at a tumour site seems inappropriate. However,
given the irradiation heterogeneity and low runs of secondary
particles (alpha and lithium), this dose does not present any
“physical issue”, for better understanding we enter the ﬁeld
of micro dosimetry. The deposit is important but on a very
small volume. Indeed, at the cell level represented by a cube
of 1m3, where the dose will ﬁll after a shock to the Boron-10,
the absorbed dose is this time about 0.5Gy/shock. Typically,
this level of radiation induces important DNA base damage
(i.e. for 1Gy per cell, there are 2000 oxidised and reduced
bases and 250 abasic sites, 1000 single and 40 double strand
breaks, and 150 clustered lesions).30 The non-localised, but
speciﬁc, irradiation suggests this methodology as a possible
source of treatment of micro-metastases (a form of metas-
reports of practical oncology and radiotherapy 1 6 ( 2 0 1 1 ) 21–31 29
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cig. 10 – Neutron spectra after interaction with attenuator (to
topped) and tumour (bottom, 26.72% neutron stopped).
asis in which secondary tumours are too minuscule to be
linically detected). Adjuvant atmospheric NBCT would focus
n destroying these micro-metastases. In addition, we must
ot forget that the exposure time and the concentration of
oron-10 (ﬁxed at 20g for the study, but could be increased
o at least 50g) are directly proportional to the number of
nteractions. If one of these parameters increases, the num-
er of interactions within the tumour will also increase. These
alues must also be contrasted with the different radiobio-
ogical effects inherent in the nature of secondary particles
epositing dose (alpha and Lithium). A relatively weak dose
ate, but with a well-targeted dose within a single cell, will
ead to radiobiological effects. The ﬁrst is related to the low
ose rate effect,31 themain effects ofwhich are repair, repopu-
ation and re-oxygenation which increase the radiosensitivity
f the cells. This process is equivalent to the process observed
uring brachytherapy. The second aspect is related to the dele-
erious effects, such as mutagenesis, observed in cells that
re not directly hit, a process called the by-stander effect.32,30
nother effect to consider is where mutations are induced
n cells that are hit only in the cytoplasm and not in the
ucleuswhereDNA is located.Normal cells (without Boron) do
ot undergo a great dose deposition, at least no greater than
uring a standard ﬂight. For these healthy cells, the ratio (con-
entration of boron) with malignant cells is about 10, revealing
he low toxicity of Boron injection at altitude in healthy
ells..12% of neutron stopped), brain (middle, 21.12% of neutron
5. Conclusions
Thepresent study shows that atmospheric neutrons can inter-
act with Boron-10 found on molecular targets (BSH and BPA).
These results were clearly predictable beforehand, but the
code developed allows to quantify simply the dose after the
penetration into the brain. However, the low ﬂux of neutrons
does not allow us to assume that it is possible to treat visi-
ble tumours (large cell colony), but rather micrometastases.
To validate this hypothesis, the presented study must be com-
pleted with laboratory experiments to quantify the real effect
of this radiation on the B-10 and biological cells. It is an
intersection of several disciplines (microdosimetry, nuclear
physics, bystander effect, low dose effect, etc.). The aim of the
presented paper is to propose to experimental teams (which
would be interested in studying the phenomena) a simple
way to calculate the dose deposition (allometric ﬁt of free
path, transmission factor of brain). Moreover, the spectrum
used as the basis for this study is a medium spectrum. Obvi-
ously, the ﬂux will vary with location and altitude. Likewise,
according to the injection protocol, the Boron concentration
within GBM as well as the exposure duration will proportion-
ally increase alongwith the on-laid dose. Sun cycle phaseswill
equally modify the on-laid dose into the tumour. Consider-
ing the parameter values before maximising the atmospheric
neutron output, we will be able to increase the absorbed dose
nd ra
r30 reports of practical oncology a
up to a hundred times. Although there are a lot of parameters
which inﬂuence the dose rate, this radiation is not entirely
uncontrollable. Previous calculation (not presented here) has
shown that the use of dosimeter may allow to quantify the
dose deposited in the tissue by neutron on Boron. The detec-
tors studied (but all neutron detectors are certainly suitable)
were luminescent materials (Optically Stimulated Lumines-
cence) of a rare-earth-doped alkaline-earth sulﬁde with 2%
of boron (SrS:Ce,Sm:B). The ﬁrst results suggest that the dose
in the tissue can be calculated by means of a dosimeter. In
brief, further studies based on radio-induced effects occurring
after the interaction between neutrons into GBM would make
it possible to establish whether an aircraft may change into a
radiotherapy room.
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